- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Laekna Inc (2105)
The Laekna share price today is 13.17, view HK 2105 stock exchange data. Track the latest Laekna share price with real-time updates on 2105 stock performance including market cap, day range, 52-week range and dividend yield. Access 2105 charts, earnings dates and analyst estimates to support your investment decisions.
Hong Kong
Currency in HKD
13.17
+0.25(+1.93%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
12.91
13.23
52 wk Range
10.30
23.50
2105 is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
12.9113.23
52 wk Range
10.3023.50
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
2105 Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
24.89
Upside
+89.02%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell
Analyst Ratings
3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 24.89
(+89.02% Upside)
Earnings
Latest Release
18-03-2026
EPS / Forecast
-0.25 / --
Revenue / Forecast
102.21M / --
Compare 2105 to Peers and Sector
Metrics to compare | 2105 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship2105PeersSector | |
|---|---|---|---|---|
P/E Ratio | −21.0x | 13.1x | −0.5x | |
PEG Ratio | −1.20 | 0.10 | 0.00 | |
Price/Book | 4.1x | 5.8x | 2.6x | |
Price / LTM Sales | 45.0x | 13.1x | 3.1x | |
Upside (Analyst Target) | 87.0% | 44.0% | 53.0% | |
Fair Value Upside | Unlock | −4.5% | 6.3% | Unlock |
Laekna, Inc., an investing holding company, engages in the discovering, development, and commercialization of therapies for patients with cancer, metabolic diseases, and liver fibrosis worldwide. The company offers LAE002, an adenosine triphosphate competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, and breast cancer; LAE001, an androgen synthesis inhibitor that inhibits CYP17A1 and CYP11B2 to treat prostate cancer; LAE005, a ligand-blocking humanized anti-PD-L1 IgG4 antibody for the treatment of triple-negative breast cancer; and LAE102, a monoclonal antibody against ActRIIA to treat obesity. It also develops LAE111, LAE112, LAE113, LAE119, and LAE120 for the treatment of cancer; LAE118, a PI3Ka mutant-selective inhibitor; LAE103 for Sarcopenia; LAE123 to treat muscle and other disease indications; LAE104 and LAE105 for the treatment of liver fibrosis; and LAE106 to treat fibrosis. The company has a collaboration with Eli Lilly and Company for the development of LAE102. Laekna, Inc. was incorporated in 2016 and is headquartered in Yuyao, China.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Laekna (2105) Share Price Today?
The Laekna share price today is 13.17.
What is the current Laekna (2105) share price and day range?
As of 22-05-2026, the Laekna share price is 13.17, with a previous close of 12.92. The share price has ranged from 12.91 to 13.23 today, while the 52-week range spans from 10.30 to 23.50.
What Is the Laekna Market Cap?
As of today, Laekna market cap is 5.43B.
What Is the Laekna (2105) Share Price Target?
The average 12-month share price target for Laekna is 24.89, with a high estimate of 27.02 and a low estimate of 23.5. 3 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +89.02% Upside potential.
What Is Laekna's Earnings Per Share (TTM)?
The Laekna EPS (TTM) is -0.59.
From a Technical Analysis Perspective, Is 2105 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
What Stock Exchange Does Laekna Trade On?
Laekna is listed and trades on the Hong Kong Stock Exchange.
What Is the Stock Symbol for Laekna?
The stock symbol for Laekna is "2105."
How Many Times Has Laekna Stock Split?
Laekna has split 0 times.
How Many Employees Does Laekna Have?
Laekna has 83 employees.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.